Lyndal Hesterberg Net Worth

Lyndal Hesterberg biography

Dr. Lyndal K. Hesterberg Ph.D. serves as Chief Scientific Officer of the Company. Dr. Hesterberg also provided counsel on clinical trial design, product development, and corporate strategy as a consultant to medical and biotech companies. Until 2012, Dr. Hesterberg was the Chief Technology Officer of Crescendo Biosciences where he was responsible for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Previously, he was the president and Chief Executive Officer of Barofold, Inc., where he led the company from product conception through its clinical stage, and recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.

What is the salary of Lyndal Hesterberg?

As the Chief Scientific Officer of Oncocyte, the total compensation of Lyndal Hesterberg at Oncocyte is $1,216,810. There are 1 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of $2,102,210.

What's Lyndal Hesterberg's mailing address?

Lyndal's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.

Insiders trading at Oncocyte

Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... и Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.

What does Oncocyte do?

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.

Oncocyte executives and stock owners

Oncocyte executives and other stock owners filed with the SEC include:

• Ronald Andrews,
  President, Chief Executive Officer, Director
• Lyndal Hesterberg,
  Chief Scientific Officer
• Mitchell Levine,
  Chief Financial Officer
• Ronald A. Andrews Jr.,
  CEO, Pres & Director
• Cavan Redmond,
  Independent Chairman of the Board
• Andrew Last,
  Independent Director
• Andrew Arno,
  Independent Director
• Melinda Griffith,
  Independent Director
• Bob Yedid,
  Investor Relations
• Douglas Ross,
  Chief Medical Officer
• Padma Sundar,
  Senior Vice President - Marketing and Market Access
• Tony Kalajian,
  Senior Vice President, Chief Accounting Officer
• Albert Parker,
  Chief Operating Officer
• Dr. Michael D. West Ph.D.,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Ekkehard Schutz M.D., Ph.D.,
  Chief Technology Officer
• Robert S. Seitz,
  Head of Immune Oncology
• Li Yu,
  VP, Controller & Principal Accounting Officer
• Gisela A. Paulsen,
  Chief Operating Officer
• Sara Riordan,
  Director of Medical Education
• Dr. Michael D. West,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Douglas T. Ross M.D., Ph.D.,
  Chief Science Officer
• William Annett,
  Advisor
• Gisela Paulsen,
  Former President and COO
• Vida Investments, Llc Kamen...,
  
• Karen B. Chapman,
  Vice President of Research
• Alfred D Kingsley,
  Director
• Don M Bailey,
  Director
• William Annett,
  President and CEO
• Michael D West,
  Director
• Kristine C. Mechem,
  VP of Marketing
• Partners, L.P.Broadwood Cap...,
  
• Anish M. John,
  Chief Financial Officer
• Aditya P. Mohanty,
  Director
• Cell Therapeutics, Inc. Lin...,
  
• James Yang Liu,
  Sr Dir., Cntlr, PAO, Int PFO
• Jennifer L. Carter,
  Director
• Li Yu,
  VP Cntrllr/Prncpl Acctng Offcr
• Partners, L.P.Bradsher Neal...,
  
• Lou Silverman,
  Director
• Josh Riggs,
  CEO and President
• John Peter Gutfreund,
  
• Andrea S. James,
  Chief Financial Officer